Predicting survival of patients with metastatic renal cell carcinoma Academic Article uri icon


MeSH Major

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Immunologic Factors
  • Interferon-alpha
  • Interleukin-2
  • Kidney Neoplasms


  • The relationship between pretreatment clinical features and survival was studied from patients treated on clinical trials for metastatic renal cell carcinoma (RCC) at the Memorial Sloan-Kettering Cancer Center. The primary analysis was performed on 670 patients treated with cytokines or chemotherapy, from which a multivariate model was derived to predict survival. Studies which followed addressed: (1) the survival of patients given interferon-α as first-line therapy; (2) a comparison of survival for patients treated with chemotherapy versus cytokine therapy; and (3) survival of patients with non-clear cell histology. Prospective identification of patients more likely to benefit from cytokine therapy is important as a stratification factor in phase III trials, and in risk-directed therapy.

publication date

  • September 2004



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00120-004-0602-x

PubMed ID

  • 15148574

Additional Document Info

start page

  • S135

end page

  • S136


  • 43


  • SUPPL. 2